Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
| Total | Transactions | Amount |
| Buys | 2 | $7,500,000 |
| Sells | 37 | $4,404,177 |
| Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
| 20 Mar 2025 16:36 | CADL | Candel Therapeutics Inc | NICHOLS WILLIAM GARRETT | Chief Medical Officer | 18 Mar 2025 | Sale | 45,316 | 8.7606 | 396,995 | D |
| 20 Mar 2025 16:36 | CADL | Candel Therapeutics Inc | BARONE FRANCESCA | Chief Scientific Officer | 18 Mar 2025 | Sale | 32,146 | 8.7623 | 281,673 | D |
| 20 Mar 2025 16:35 | CADL | Candel Therapeutics Inc | TAK PAUL PETER | Chief Executive Officer | 18 Mar 2025 | Sale | 25,772 | 8.7701 | 226,023 | D |
| 20 Mar 2025 16:35 | CADL | Candel Therapeutics Inc | TAK PAUL PETER | Chief Executive Officer | 19 Mar 2025 | Sale | 400 | 9.0025 | 3,601 | D |
| 20 Mar 2025 16:35 | CADL | Candel Therapeutics Inc | TYAGARAJAN SESHU | Chief Technology Officer | 17 Mar 2025 | Sale A | 31,278 | 8.8224 | 275,947 | D |
| 19 Mar 2025 16:12 | CADL | Candel Therapeutics Inc | TYAGARAJAN SESHU | Chief Technology Officer | 17 Mar 2025 | Sale | 31,278 | 8.8224 | 275,947 | D |
| 19 Mar 2025 16:06 | CADL | Candel Therapeutics Inc | SCHOCH CHARLES | See Remarks | 17 Mar 2025 | Sale | 5,000 | 8.8338 | 44,169 | D |
| 17 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | BARONE FRANCESCA | Chief Scientific Officer | 15 Jan 2025 | Sale | 13,534 | 7.225 | 97,783 | D |
| 17 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | TYAGARAJAN SESHU | Chief Technology Officer | 15 Jan 2025 | Sale | 14,322 | 7.225 | 103,476 | D |
| 17 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | SCHOCH CHARLES | See Remarks | 15 Jan 2025 | Sale | 9,511 | 7.225 | 68,717 | D |
| 17 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | TAK PAUL PETER | Chief Executive Officer | 15 Jan 2025 | Sale | 21,704 | 7.225 | 156,811 | D |
| 17 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | NICHOLS WILLIAM GARRETT | Chief Medical Officer | 15 Jan 2025 | Sale | 10,428 | 7.225 | 75,342 | D |
| 10 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | BARONE FRANCESCA | Chief Scientific Officer | 08 Jan 2025 | Sale | 13,673 | 8.2182 | 112,367 | D |
| 10 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | SCHOCH CHARLES | See Remarks | 08 Jan 2025 | Sale | 9,971 | 8.2182 | 81,944 | D |
| 10 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | TAK PAUL PETER | Chief Executive Officer | 08 Jan 2025 | Sale | 21,172 | 8.2182 | 173,996 | D |
| 10 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | TYAGARAJAN SESHU | Chief Technology Officer | 08 Jan 2025 | Sale | 14,545 | 8.2182 | 119,534 | D |
| 10 Jan 2025 16:30 | CADL | Candel Therapeutics Inc | NICHOLS WILLIAM GARRETT | Chief Medical Officer | 08 Jan 2025 | Sale | 10,799 | 8.2183 | 88,749 | D |
| 18 Dec 2024 16:11 | CADL | Candel Therapeutics Inc | MANNING PAUL B | Director | 16 Dec 2024 | Purchase | 500,000 | 6 | 3,000,000 | I |
| 18 Dec 2024 16:11 | CADL | Candel Therapeutics Inc | MANNING PAUL B | Director | 16 Dec 2024 | Purchase | 750,000 | 6 | 4,500,000 | I |
| 03 Dec 2024 17:48 | CADL | Candel Therapeutics Inc | TYAGARAJAN SESHU | Chief Technology Officer | 29 Nov 2024 | Sale | 20,392 | 4.5556 | 92,898 | D |
| 03 Dec 2024 17:48 | CADL | Candel Therapeutics Inc | TAK PAUL PETER | Chief Executive Officer | 29 Nov 2024 | Sale | 48,847 | 4.5556 | 222,527 | D |
| 03 Dec 2024 17:47 | CADL | Candel Therapeutics Inc | NICHOLS WILLIAM GARRETT | Chief Medical Officer | 29 Nov 2024 | Sale | 13,935 | 4.5556 | 63,482 | D |
| 03 Dec 2024 17:46 | CADL | Candel Therapeutics Inc | BARONE FRANCESCA | Chief Scientific Officer | 29 Nov 2024 | Sale | 22,081 | 4.5556 | 100,592 | D |
| 15 Oct 2024 17:59 | CADL | Candel Therapeutics Inc | AGUILAR-CORDOVA ESTUARDO | 10% | 11 Oct 2024 | Sale | 15,000 | 6.05 | 90,750 | D |
| 15 Oct 2024 17:59 | CADL | Candel Therapeutics Inc | AGUILAR-CORDOVA ESTUARDO | 10% | 14 Oct 2024 | Sale | 15,000 | 6.02 | 90,300 | D |
| 15 Oct 2024 17:59 | CADL | Candel Therapeutics Inc | AGUILAR-CORDOVA ESTUARDO | 10% | 15 Oct 2024 | Sale | 10,412 | 6.03 | 62,784 | D |
| 03 Oct 2024 18:19 | CADL | Candel Therapeutics Inc | AGUILAR-CORDOVA ESTUARDO | 10% | 01 Oct 2024 | Sale | 6,214 | 7.0091 | 43,555 | D |
| 03 Oct 2024 18:19 | CADL | Candel Therapeutics Inc | AGUILAR-CORDOVA ESTUARDO | 10% | 02 Oct 2024 | Sale | 26,988 | 6.92 | 186,757 | D |
| 03 Oct 2024 18:19 | CADL | Candel Therapeutics Inc | AGUILAR-CORDOVA ESTUARDO | 10% | 03 Oct 2024 | Sale | 1,800 | 6.85 | 12,330 | D |
| 19 Jul 2024 08:31 | CADL | Candel Therapeutics Inc | TYAGARAJAN SESHU | Chief Technology Officer | 17 Jul 2024 | Sale | 14,851 | 6.4726 | 96,125 | D |
| 19 Jul 2024 08:29 | CADL | Candel Therapeutics Inc | TAK PAUL PETER | Chief Executive Officer | 17 Jul 2024 | Sale | 22,528 | 6.4726 | 145,815 | D |
| 19 Jul 2024 08:28 | CADL | Candel Therapeutics Inc | SCHOCH CHARLES | See Remarks | 17 Jul 2024 | Sale | 9,884 | 6.4726 | 63,975 | D |
| 19 Jul 2024 08:26 | CADL | Candel Therapeutics Inc | NICHOLS WILLIAM GARRETT | Chief Medical Officer | 17 Jul 2024 | Sale | 10,875 | 6.4726 | 70,390 | D |
| 19 Jul 2024 08:24 | CADL | Candel Therapeutics Inc | BARONE FRANCESCA | Chief Scientific Officer | 17 Jul 2024 | Sale | 14,051 | 6.4726 | 90,947 | D |
| 15 Jul 2024 08:36 | CADL | Candel Therapeutics Inc | TYAGARAJAN SESHU | Chief Technology Officer | 11 Jul 2024 | Sale | 13,330 | 5.9734 | 79,625 | D |
| 15 Jul 2024 08:35 | CADL | Candel Therapeutics Inc | TAK PAUL PETER | Chief Executive Officer | 11 Jul 2024 | Sale | 20,293 | 5.9734 | 121,218 | D |
| 15 Jul 2024 08:34 | CADL | Candel Therapeutics Inc | SCHOCH CHARLES | See Remarks | 11 Jul 2024 | Sale | 8,897 | 5.9734 | 53,145 | D |
| 15 Jul 2024 08:32 | CADL | Candel Therapeutics Inc | NICHOLS WILLIAM GARRETT | Chief Medical Officer | 11 Jul 2024 | Sale | 9,769 | 5.9734 | 58,354 | D |
| 15 Jul 2024 08:30 | CADL | Candel Therapeutics Inc | BARONE FRANCESCA | Chief Scientific Officer | 11 Jul 2024 | Sale | 12,645 | 5.9734 | 75,534 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)